$980 Million is the total value of Sarissa Capital Management LP's 12 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRWD | IRONWOOD PHARMACEUTICALS INC | $159,915,000 | +26.6% | 14,040,000 | 0.0% | 16.32% | +9.8% | |
| ALKS | Buy | ALKERMES PLC | $158,602,000 | +22.3% | 7,950,000 | +1.6% | 16.19% | +6.1% |
| BIIB | BIOGEN INC | $157,444,000 | -13.7% | 643,000 | 0.0% | 16.07% | -25.2% | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $153,182,000 | +15.8% | 928,100 | 0.0% | 15.63% | +0.4% | |
| ALXN | ALEXION PHARMACEUTICALS INC | $124,638,000 | +36.5% | 797,740 | 0.0% | 12.72% | +18.4% | |
| INVA | INNOVIVA INC | $79,469,000 | +18.6% | 6,414,000 | 0.0% | 8.11% | +2.8% | |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $77,887,000 | +47.4% | 2,927,000 | +3.2% | 7.95% | +27.8% |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $60,903,000 | +264.8% | 8,175,000 | +68.2% | 6.22% | +216.2% |
| SRSAW | New | SARISSA CAPITAL ACQUISITN COw exp 10/23/202 | $4,999,000 | – | 3,333,333 | +100.0% | 0.51% | – |
| RGLS | REGULUS THERAPEUTICS INC | $2,499,000 | +162.8% | 1,851,851 | 0.0% | 0.26% | +127.7% | |
| MRTX | MIRATI THERAPEUTICS INC | $219,000 | +31.9% | 1,000 | 0.0% | 0.02% | +10.0% | |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS INC | $23,000 | -100.0% | 950 | -99.9% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.